Nexalin Announces Additional Significant Data Regarding Gen-2 SYNC Neurostimulation Device

(RTTNews) - Nexalin Technology, Inc. (NXL), Wednesday announced additional positive clinical data, demonstrating that its proprietary 15 milliamp Gen-2 Nexalin DIFS technology showed improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer's disease.

Additionally, the patients showed a significant improvement in Mini-Mental State Examination and Montreal Cognitive Assessment scores compared to the sham group.

The device also enhanced functional connectivity between the hippocampus and key cortical regions, increased functional connectivity across broader cognitive networks, and improved connectivity between the hippocampus and middle cingulate gyrus.

The findings, published in Radiology, further highlights the company's long term commitment to deliver safe, and effective alternatives to pharmacologic treatments for neurodegenerative conditions and their associated costs and side effects.

Currently, NXL is surging 96.12 percent, to $1.83 on the Nasdaq.